Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-20
2007-03-20
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S153000, C546S157000
Reexamination Certificate
active
10713722
ABSTRACT:
Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPARgamma and RXR/PPARalpha heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders
REFERENCES:
patent: 6369055 (2002-04-01), Jeppesen et al.
patent: 2002/0065268 (2002-05-01), Jeppesen et al.
patent: 2002/0082292 (2002-06-01), Sahoo et al.
patent: 2002/0103242 (2002-08-01), Sahoo et al.
patent: 2005/0020684 (2005-01-01), Brooks et al.
patent: WO94/13650 (1994-06-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 00/08002 (2000-02-01), None
patent: WO 01/55085 (2001-08-01), None
patent: WO 02/26729 (2002-04-01), None
Buckle, D.R., Bioorganic & Medicinal Chemistry, Letters, vol. 6, No. 17, pp. 2127-2130, 1996.
T.M. Wilson, et al, “The PPAR's from orphan receptors to drug discovery,” J. Med. Chem. 2000 43:527-550, A.
Chawla, et al, Nuclear receptors and lipid physiology “Opening the X-files”, Science, 2001, vol. 294, 1866-1870.
Keller & Wahli, Peroxisome Proliferator-Activated Receptors A Link Between Endocrinology and Nutrition, TEM vol. 4, No. 9, 1993, 291-296.
Wang YX et al, Peroxisome-Proliferator-Activated Receptor o Activaaaaaates Fat Metabolism to Prevent Obesity, Cell, Apr. 18, 2003, vol. 113, 159-170.
Lee, Ch et al, Transcriptional Repression of Atherogenic Inflammation: Modulation by PPAR's, Science, vol. 302, Oct. 17, 2003, pp. 453-457.
Deng Tuo
Li Zhi-bin
Liao Chenzhong
Liu Zhende
Lu Xian-Ping
Buchanan Ingersoll & Rooney P.C.
Chipscreen Biosciences, Ltd.
Seaman D. Margaret
LandOfFree
Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3729673